In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL SHR2554: Oral EZH2 Inhibitor in R/R PTCL SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL Presenters: Max S. Topp, MD Head of Hematology and Clinical CAR-T Program Lead Associated Professor Medinische Klinik und Poliklinkik II University of Wurzburg Wurzburg, Germany Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum- University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program: https://bit.ly/4obcJPI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
